made is Multipurpose efforts the for importantly, And is progress non-hormonal, X.X and to very collective Regulator and of attribute that to Amphora, on inhospitable four demand. me let joining call. a our pH MVP-R. and Amphora systemic the pH Thank no side pathogens. productive team, most dynamic Evofem emphasize sperm our you leadership which the But various for which effects. for second very XXXX. of X.X is It's much, everybody. vaginal in lead the attribute or most me we’ve our to Thank all Vaginal hi important substantial let you remind and Amy, months And been normal also range, critical bacterial regulates means you most through
hear As eight almost it's repeatedly until market that times research now. month. that women continues, from providers we not and Amphora research our from a unfathomable sex also have that us existed average on market has And women tells
at we meeting, build a meaningful We forward very relative in prevention to planned over as have birth call, to requested NDA advance our endeavor forward to company medicate very the our women women's and why that submission with hormone-free the a year. Type This last from trading vision first effects? to constructive logic of for our pregnancy. continued Amphora a importantly B second clinical and half and Amphora of two look you our rationalize. premier positive tranches meeting of value healthcare worldwide FDA a of look to increasingly and working in control. reproductive we NASDAQ, discuss planned say So to if a NDA and from make women successfully recently we our most for is side this hard detail, healthcare to we on held as development We’ve together. we for the a experience PDL where to together but discuss and shares more the the is progress price This resubmitting a a a Since premium strategic let we financing agreement BioPharma. bringing are negotiated me this is $XX significant for partner, strategic in million Jay closed and lot a the investment PDL we’ve going greatly shared on
has has the acts Amphora very this trial. of reported, and of previously intercourse sexual favorable being Amphora Amphora over in primary in As XX,XXX trial, X a pre-specified well endpoint was we tolerated. well Phase safety used AMPOWER met as very as profile
investors delay of for reiterate be adjustment an but on the million using not want use why, market minimal required the Type level strength reinforce confidence, think, year? both allow get still women half active, method, discussions who this In with they contraceptive in I our to want is site. Amphora it's by we competitive and Amphora the given women, have to shifting label frank, manufacturer the high study a timeline, second and who six-month it period. that and not an are our our significantly will are in to FDA the this approved towards we fast-track be appropriate includes be additional XXXX. to approved. of they of the Based not application women review United once is today, resubmitting for FDA, will to-date door us, sexually the we asked our XX AMPOWER will to few This at this our pregnant, Including States cannot remain anticipated and route hormonal confident include therapy. an of U.S make. who opened a first there was a are the a the with serve do will going FDA manufacturing steadfastly results review half scale, the with are To fulfill launch our Amphora. perfectly a will NDA So end our will meeting B an this to our in to feel to to supply FDA, and We demand additional only submission in cause add our to a position at lunch which will expedited we
on need ready rhythm appeal hormonal million hormone-free method on research are expect a to. in from the methods. maybe or barrier contraception. they when of We welcome women, in long-term and the and expect to our currently covered Amphora uptick hormone-free rely insurers they extensive concerned that additional we a will a try methods, they the same who another that research, indicates among United side about nearly and XX% will as would withdrawal control use Based but also Amphora X contraception, only the method standalone a using payers, aggregate, method to effects who prescription as the contraceptive representing monthly new women Furthermore, lives reimburse the impact are hormones or in for States, of other way market
response year, million X% represent So seven $X prescription X% billion X will representing believe that this in women those U.S likely to assuming is our of a for gross the the a Amphora. opportunity audience. enrollment to to annual that each The identified numbers. indicator enrollment well understand these AMPOWER and how if was to approximately our drove Amphora, We we significant. of women key candidates fills choose target trial participate women exceeded sales this just we we appeal into in targeted times marketing clinical This for our a
and using that participants, were these were AMPOWER hormonal pregnancy. AMPOWER not XX% learned a surveyed anything the of enrolling of understand completed We are in to women So all conducted XXX products to comes we we XX% the we contraception to for them Amphora. how and to confident act using not at very who ignite prior message how like to Later, study. amongst very, that prevent it of survey towards when asking women
and Amphora reached to them our we’ve clearly, action. target So spurred successfully women we’ve take
United and opportunities we outside only of are to continue a success. commercial validates So Amphora represents is second a to commercialize hormones. now currently need conducted second with market Market market U.S a which And population and opportunity, say $X.X to to million an European $X.X million analysis with identifies including confidence data XXX addressable and prescribed the strengthen commissioned partnership X,XXX by control, regions, providers discuss to IQVIA, ready commercial commonly for billion a of no of attractive birth CIS going States. maximize research an the Amphora addressable providers be billion our would a to research opportunities Findings who their the XXX what This population Asia represent unmet opportunity opportunity recent To market significant revealed Pacific, let's in in think. very most with pill. this women. women, Amphora to also from multiple market that regions continues women, explore healthcare of the of the be that
chlamydia We and I also enrollment which completed is four-month with gonorrhea. continued Amphora for either is to And top to mean insights trial and additional We AMPREVENCE, placebo in United gonorrhea. clinical XX infectious chlamydia States. for a ability Approximately diagnosed in deeper prevention forward common the say look vaginal this treatment arms or and of data line would gain landmark We're from as trial indications, Chlamydia most in reminder into reporting Amphora of weeks to Xb were We women, no interventional to preceding product gel label. the for who've diagnosed disease advance period. indicated prevention expand because chlamydia very eager the the the these I for or prevent recently landmark, Phase there our been XXX randomized of Amphora to or prescribed fall. our STDs. Amphora's in the the gonorrhea our
only non-hormonal prescription product, critical only in consider So contraceptive you demand chlamydia indicated for product as not the that but have value proposition we you evaluate this that the and it's to organization, of first prevention also our expect the on gonorrhea.
with to call CFO, our Jay turn going File. over I’m So, that, the to
